...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Lymphatic Microvessel Density, VEGF-C, and VEGFR-3 Expression in Different Molecular Types of Breast Cancer.
【24h】

Lymphatic Microvessel Density, VEGF-C, and VEGFR-3 Expression in Different Molecular Types of Breast Cancer.

机译:乳腺癌不同分子类型中的淋巴微血管密度,VEGF-C和VEGFR-3表达。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Breast cancer is a heterogeneous disease and five major distinct molecular types have been characterized by gene analysis and immunohistochemistry. The molecular types of breast cancer have different behavior, a particular profile of response to therapy, reflected in the differential survival of patients. Previous findings showed a particular preference for lymph node and distant metastases of different molecular types, but the specific lymphangiogenic profile of these types is lacking. PATIENTS AND METHODS: We investigated the differential expression vascular endothelial growth factor-C (VEGF-C), vascular endothelial growth factor receptor-3 (VEGFR-3) and D2-40 by immunohistochemistry, to evaluate lymphangiogenesis and the lymphatic microvessel density (LMVD), in patients with breast cancer, stratified according to the molecular classification. RESULTS: There was a differential expression of VEGF-C/VEGFR-3 and D2-40 in different molecular types of breast cancer, with highest level of expression for these markers being found in HER2 and luminal B types and the lowest in basal-like type. The lowest value of both intratumoral and peritumoral LMVD were found in normal-like type breast cancer. VEGF-C expression did not correlate with the grade of the tumor, but a significant correlation was found with lymph node metastasis. VEGFR-3 expression was found in 66.66% of the cases and correlated with the expression of VEGF-C in tumor cells. There was a positive correlation between VEGF-C, VEGFR-3 and LMVD only in the HER2 type, and a positive correlation in HER2 and normal-like types with VEGFR-3 expression in tumor cells. In addition, there was a correlation between HER2 type, VEGF-C and VEGFR-3 expression in tumor cells and lymphatic endothelium, respectively, and LMVD. CONCLUSION: Our results support a differential signature of lymphangiogenesis in different molecular types of breast cancer and these findings may have a direct impact on prognosis and therapeutic strategy of this disease.
机译:背景:乳腺癌是一种异质性疾病,通过基因分析和免疫组化已鉴定出五种主要的分子类型。乳腺癌的分子类型具有不同的行为,对治疗反应的特定特征,反映在患者的不同存活率上。先前的发现显示特别喜欢不同分子类型的淋巴结和远处转移,但是缺乏这些类型的特定淋巴管生成特征。病人和方法:我们通过免疫组织化学研究了差异表达的血管内皮生长因子-C(VEGF-C),血管内皮生长因子受体3(VEGFR-3)和D2-40,以评估淋巴管生成和淋巴微血管密度(LMVD) ),在乳腺癌患者中,根据分子分类分层。结果:在不同分子类型的乳腺癌中VEGF-C / VEGFR-3和D2-40表达差异,其中这些标记物的最高表达水平在HER2和管腔B型中最低,而在基底样中最低类型。在正常型乳腺癌中,瘤内和瘤周围LMVD的最低值。 VEGF-C的表达与肿瘤的分级无关,但与淋巴结转移密切相关。在66.66%的病例中发现VEGFR-3表达,并且与肿瘤细胞中VEGF-C的表达相关。仅在HER2类型中VEGF-C,VEGFR-3和LMVD之间存在正相关,而在HER2和正常类型中,VEGF-C与VEGFR-3在肿瘤细胞中的表达呈正相关。另外,在肿瘤细胞和淋巴内皮中的HER2类型,VEGF-C和VEGFR-3表达分别与LMVD之间存在相关性。结论:我们的结果支持在不同分子类型的乳腺癌中淋巴管生成的不同特征,这些发现可能对该疾病的预后和治疗策略有直接影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号